Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
|Articles|December 1, 2006
Botox tx for osteoarthritis
Washington - Botox may relieve severe pain from osteoarthritis of the knee, new research suggests.
Advertisement
Washington - Botox may relieve severe pain from osteoarthritis of the knee, new research suggests.
In interim data from a randomized, placebo-controlled trial, injections of botulinum toxin type A significantly reduced severe pain and improved function, researchers said.
In an open-label study, 10 of 15 patients showed improvement in pain of 50 percent or greater.
Advertisement
Related to this article
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
2
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
3
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
4
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
5